During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

For patients with Waldenström macroglobulinemia (WM), transitioning from ibrutinib (Imbruvica) to zanubrutinib (Brukinsa) may offer comparable clinical outcomes, as suggested by interim data from a ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.

Findings from a study on the role of exosomal non-coding RNAs (ncRNAs) in the progression of multiple myeloma (MM), with a specific focus on sex-based differences, show that while male and female ...

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with ...

Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with ...

Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...